SCHEMBL5129060

SCHEMBL5129060

Cc1c2c(=O)n(CCCNC(=O)OC(C)(C)C)c3cc4c(cc3c2nn1C(=O)OC(C)(C)C)CCCC4

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.42
CNR2 P34972 1/20 0.41
PLK1 P53350 4/20 0.37
DRD2 P14416 3/20 0.36
STING1 Q86WV6 1/20 0.36
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35
BRD4 O60885 1/20 0.34
CHEK1 O14757 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4005010 0.86 DYRK1A (0.46) DYRK1ACNR2PLK1STING1TDP1
SCHEMBL5129516 0.86 CNR2 (0.41) DYRK1ACNR2DRD2STING1MEN1
SCHEMBL4017813 0.85 CHEK1 (0.33) DYRK1AALDH1A1CHEK1
SCHEMBL4014749 0.85 CHEK1 (0.33) DYRK1AALDH1A1CHEK1
SCHEMBL4023100 0.85 CHEK1 (0.33) DYRK1AALDH1A1CHEK1
SCHEMBL5132256 0.83 CHEK1 (0.33) CHEK1
SCHEMBL5126809 0.78 ATR (0.39) DYRK1ACNR2PLK1STING1MEN1
SCHEMBL14192079 0.75 ATR (0.37) DYRK1ACNR2PLK1MEN1ALDH1A1
SCHEMBL6508889 0.72 ATR (0.42) DYRK1ACNR2PLK1STING1BRD4
SCHEMBL6511027 0.72 ATR (0.42) DYRK1ACNR2PLK1DRD2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114016-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2008-05-15 US disclosed
US-20080114016-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2008-05-15 US disclosed
EP-1835918-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2007-09-26 EP disclosed
WO-2006074281-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114016-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, BUB1B DYRK1A 634/4885CNR2 4397/4885PLK1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.